MCS-18, a natural product isolated from Helleborus purpurascens, inhibits maturation of dendritic cells in ApoE-deficient mice and prevents early atherosclerosis progression

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 263-272

  Dietel, Barbara ^a   Muench, Rabea ^a   Kuehn, Constanze ^a   Kerek, Franz ^b   Steinkasserer, Alexander ^a   Achenbach, Stephan ^a   Garlichs, Christoph D ^a   Zinser, Elisabeth ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b DoNatur GmbH   (Germany)

Author keywords

ApoE deficient mice; Atherosclerosis; Autoimmunity; Dendritic cells; MCS 18

Indexed keywords

APOLIPOPROTEIN E; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MCS 18; NATURAL PRODUCT; SODIUM CHLORIDE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; MCS-18;

ANIMAL EXPERIMENT; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; BODY WEIGHT; CELL MATURATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; DRUG INHIBITION; FLOW CYTOMETRY; HELLEBORUS PURPURASCENS; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; VERATRUM; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL PRODUCTS; DENDRITIC CELLS; DIET, HIGH-FAT; DISEASE PROGRESSION; INFLAMMATION; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC;

EID: 84921666014     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.915     Document Type: Article

References (27)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEngl J Med 2005, 352:1685-1695.
2. Jiang J.A., Xue Q., Liu C.P., Gao L., Zhang G.B., Chen Y.J., et al. Expression of B7-H3 costimulatory molecule in peripheral blood of myasthenia gravis patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012, 28:856-859.
3. Krams R., Segers D., Mousavi Gourabi B., Maat W., Cheng C., van Pelt C., et al. Inflammation and atherosclerosis: mechanisms underlying vulnerable plaque. JInterv Cardiol 2003, 16:107-113.
4. Koltsova E.K., Ley K. How dendritic cells shape atherosclerosis. Trends Immunol 2011, 32:540-547.
5. Bobryshev Y.V., Lord R.S. S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res 1995, 29:689-696.
6. Cartland S.P., Jessup W. Dendritic cells in atherosclerosis. Curr Pharm Des 2013, 19:5883-5890.
7. Alderman C.J., Bunyard P.R., Chain B.M., Foreman J.C., Leake D.S., Katz D.R. Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment?. Cardiovasc Res 2002, 55:806-819.
8. Doring Y., Manthey H.D., Drechsler M., Lievens D., Megens R.T., Soehnlein O., et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012, 125:1673-1683.
9. Langhoff E., Steinman R.M. Clonal expansion of human T lymphocytes initiated by dendritic cells. JExp Med 1989, 169:315-320.
10. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
11. Aicher A., Heeschen C., Mohaupt M., Cooke J.P., Zeiher A.M., Dimmeler S. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 2003, 107:604-611.
12. Littmann L., Rossner S., Kerek F., Steinkasserer A., Zinser E. Modulation of murine bone marrow-derived dendritic cells and B-cells by MCS-18 a natural product isolated from Helleborus purpurascens. Immunobiology 2008, 213:871-878.
13. Kerek F., Szegli G., Cremer L., Lupu A.R., Durbaca S., Calugaru A., et al. The novel arthritis-drug substance MCS-18 attenuates the antibody production invivo. Acta Microbiol Immunol Hung 2008, 55:15-31.
14. Nica S., Stanescu L., Krejci G. Arandomised double blind phase II study with injection containing MCS-18 as active substance in 3+ 1 doses versus placebo in the treatment of painful shoulder periarthritis. Clin Trial Rep 2005, 1-216.
15. Seifarth C., Littmann L., Resheq Y., Rossner S., Goldwich A., Pangratz N., et al. MCS-18, a novel natural plant product prevents autoimmune diabetes. Immunol Lett 2011, 139:58-67.
16. Horstmann B., Zinser E., Turza N., Kerek F., Steinkasserer A. MCS-18, a novel natural product isolated from Helleborus purpurascens, inhibits dendritic cell activation and prevents autoimmunity as shown invivo using the EAE model. Immunobiology 2007, 212:839-853.
17. Buono C., Pang H., Uchida Y., Libby P., Sharpe A.H., Lichtman A.H. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004, 109:2009-2015.
18. Thomas R., Lipsky P.E. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. JImmunol 1994, 153:4016-4028.
19. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol 2002, 23:445-449.
20. Mahnke K., Johnson T.S., Ring S., Enk A.H. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. JDermatol Sci 2007, 46:159-167.
21. von der Thusen J.H., Kuiper J., van Berkel T.J., Biessen E.A. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003, 55:133-166.
22. Pilette C., Ouadrhiri Y., Van Snick J., Renauld J.C., Staquet P., Vaerman J.P., et al. IL-9 inhibits oxidative burst and TNF-alpha release in lipopolysaccharide-stimulated human monocytes through TGF-beta. JImmunol 2002, 168:4103-4111.
23. Jovinge S., Ares M.P., Kallin B., Nilsson J. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol 1996, 16:1573-1579.
24. Grohmann U., Van Snick J., Campanile F., Silla S., Giampietri A., Vacca C., et al. IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10. JImmunol 2000, 164:4197-4203.
25. Kyaw T., Winship A., Tay C., Kanellakis P., Hosseini H., Cao A., et al. Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice. Circulation 2013, 127:1028-1039.
26. Yilmaz A., Lochno M., Traeg F., Cicha I., Reiss C., Stumpf C., et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004, 176:101-110.
27. Dietel B., Cicha I., Voskens C.J., Verhoeven E., Achenbach S., Garlichs C.D. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis 2013, 230:92-99.